Showing results (11-20 of 107) with videos related to

Sort By:
Pageof 11
Cell Reports|April 17, 2026
Gene-culture coevolution shapes olfactory receptor gene diversity in Orang Asli populationsYueyang Ma, Boon-Peng Hoh, Shuhua Xu, et al.
Scientific Reports|February 19, 2016
Ancestry variation and footprints of natural selection along the genome in Latin American populationsLian Deng, Andrés Ruiz-Linares, Shuhua Xu, et al.
Zhongguo Zhen Jiu = Chinese Acupuncture & Moxibustion|May 26, 2010
[Observation on therapeutic effect of acupoint sticking at Neiguan (PC 6) and Xinshu (BL 15) for treatment of bradycardia]Lian-deng Xu, Yu-xia Zhang, Yan-hua Zheng
STAR Protocols|June 6, 2022
A protocol for applying a population-specific reference genome assembly to population genetics and medical studiesLian Deng, Bo Xie, Yimin Wang, et al.
Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics|February 19, 2009
[Distribution and antibiotic resistance of pathogens isolated from children with infectious diarrhea in Guangzhou]Yong-Qiang Xie, Qiu-Lian Deng, Yan Guo, et al.
RSC Advances|June 7, 2023
Ni-Al layered double hydroxide-coupled layered mesoporous titanium dioxide (Ni-Al LDH/LM-TiOLi-Yuan Zhang, Yan-Lin Han, Min Liu, et al.
Journal of Applied Biomaterials & Functional Materials|June 18, 2016
A novel and facile method to rapidly synthesize Ce0.8Zr0.2O2 nanoparticles for CO preferential oxidation in H2-rich streamNengsheng Liu, Lian Deng, Jing Wang, et al.
Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics|June 30, 2009
[Investigation of campylobacter jejuni infection in children with diarrhea in Guangzhou]Yong-Qiang Xie, Zhen-Wen Zhou, Yan Guo, et al.
Frontiers in Pharmacology|September 5, 2025
Cost-effectiveness analysis of toripalimab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and ChinaMing Ouyang, Jiangbo Wang, Gaofeng Zhang, et al.
Clinical Drug Investigation|February 1, 2024
Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care SystemWenwang Lang, Lian Deng, Bei Huang, et al.
Pageof 11